Floatz logo

as1404

Advanced or Recurrent Solid Tumors

Novartis PharmaceuticalsPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Advanced or Recurrent Solid Tumors cohort.

Asset / SponsorPhaseRating
FGF/FGFR PATHWAY INHIBITOR E7090
National Cancer Center, Japan
Phase 2CCC
Talzenna
Center Trials & Treatment
Phase 1CC
Tislelizumab
Peking University
Phase 1CC
evm16
Peking University
Phase 1CC
rc48-adc
Peking University
Phase 1CC
Pyrotinib
Peking University
Phase 1CC

Same molecule, other indications

as1404 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
lung cancerDormant
CC
Indicative ·
44 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →